The goal of the Clinical Trials Core is to provide the expertise and infrastructure to facilitate the completion of all of the patient-based components of research proposed in this Program Project Grant. The core goals will be achieved through accomplishing the following specific aims. 1. Conduct a phase I clinical and pharmacokinetic/pharmacodynamic (PK/PD) trial with HIF1-alpha inhibitor, PX-478, given in combination with radiation therapy for bone metastasesfrom breast cancer ( Project 1, Pi- Garth Powis, D. Phil). 2. Conduct a phase II clinical trial with the new agent imexon for patients with gemcitabine-refractory pancreatic cancer (Project 2, Pi-Robert Dorr, Ph.D). 3. Help integrate new imaging technology that focuses on the measurement of stress response and hypoxia in solid tumors into clinical trials (Project 3, Pi-Robert Gillies, Ph.D.). 4. Design and conduct additional phase I and II clinical trials with other novel agents that interfere with tumor response to stress and hypoxia such as PIS kinase inhibitor PX-886 (Project 1), cyanaziridine analogs (Project 2), and possibly other agents (i.e. mTOR inhibitor) alone or in combination with radiation or chemotherapy drugs. The core C will accomplish these aims by assembling a team of clinical investigators and support research staff at the Arizona Cancer Center that will work closely with project and core leaders on translating novel therapeutic and diagnostic concepts from the bench to the bedside.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA017094-31
Application #
8136328
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2010-09-01
Budget End
2011-08-31
Support Year
31
Fiscal Year
2010
Total Cost
$191,247
Indirect Cost
Name
University of Arizona
Department
Type
DUNS #
806345617
City
Tucson
State
AZ
Country
United States
Zip Code
85721
Landowski, Terry H; Guntle, Gerald P; Zhao, Dezheng et al. (2016) Magnetic Resonance Imaging Identifies Differential Response to Pro-Oxidant Chemotherapy in a Xenograft Model. Transl Oncol 9:228-35
Barrett, Harrison H; Alberts, David S; Woolfenden, James M et al. (2016) Therapy operating characteristic curves: tools for precision chemotherapy. J Med Imaging (Bellingham) 3:023502
Chang, Hae Ryung; Nam, Seungyoon; Kook, Myeong-Cherl et al. (2016) HNF4? is a therapeutic target that links AMPK to WNT signalling in early-stage gastric cancer. Gut 65:19-32
Malm, Scott W; Hanke, Neale T; Gill, Alexander et al. (2015) The anti-tumor efficacy of 2-deoxyglucose and D-allose are enhanced with p38 inhibition in pancreatic and ovarian cell lines. J Exp Clin Cancer Res 34:31
Samulitis, Betty K; Pond, Kelvin W; Pond, Erika et al. (2015) Gemcitabine resistant pancreatic cancer cell lines acquire an invasive phenotype with collateral hypersensitivity to histone deacetylase inhibitors. Cancer Biol Ther 16:43-51
Nam, S; Chang, H R; Kim, K-T et al. (2014) PATHOME: an algorithm for accurately detecting differentially expressed subpathways. Oncogene 33:4941-51
Dragovich, T; Laheru, D; Dayyani, F et al. (2014) Phase II trial of vatalanib in patients with advanced or metastatic pancreatic adenocarcinoma after first-line gemcitabine therapy (PCRT O4-001). Cancer Chemother Pharmacol 74:379-87
Exley, Mark A; Hand, Laura; O'Shea, Donal et al. (2014) Interplay between the immune system and adipose tissue in obesity. J Endocrinol 223:R41-8
Zhang, Xiaomeng; Pagel, Mark D; Baker, Amanda F et al. (2014) Reproducibility of magnetic resonance perfusion imaging. PLoS One 9:e89797
Jagadish, Bhumasamudram; Ozumerzifon, Tarik J; Roberts, Sue A et al. (2014) IMPROVED SYNTHESIS OF 10-(2-ALKYLAMINO-2-OXOETHYL)-1,4,7,10-TETRAAZACYCLODODECANE-1,4,7-TRIACETIC ACID DERIVATIVES BEARING ACID-SENSITIVE LINKERS. Synth Commun 44:

Showing the most recent 10 out of 314 publications